Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy (opens in new tab)

BackgroundImmune checkpoint inhibitors (ICIs) have transformed cancer therapy but frequently induce immune-related adverse events (irAEs), which can disrupt treatment and worsen outcomes. The mechanisms predisposing certain individuals to irAEs remain unclear, and reliable strategies for early prediction and prevention are urgently needed.MethodsWe analyzed pre-treatment peripheral blood mononuclear cell (PBMC) transcriptomic data from 88 patients receiving ICIs, including 22 who subsequently...